Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 4, 2005, Pages 354-360

  Ramanathan, Ramesh K ^a,b   Ramalingam, Sakkaraiappan ^a,b   Egorin, Merrill J ^a,b   Belani, Chandra P ^a,b   Potter, Douglas M ^b,c   Fakih, Marwan ^a   Jung, Laura L ^b   Strychor, Sandra ^b   Jacobs, Samuel A ^a,b   Friedland, David M ^a   Shin, Dong M ^a,b   Chatta, Gurkamal S ^a,b   Tutchko, Susan ^b   Zamboni, William C ^a,b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Capecitabine; Combination; Docetaxel; Pharmacokinetics; Phase I

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BILE DUCT CANCER; BLADDER CANCER; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARCINOMA; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; EDEMA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MESOTHELIOMA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASMS; TAXOIDS;

EID: 20144378065     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0909-8     Document Type: Article

References (23)

1. Miwa M, Ura M, Nishida M, et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281
2. Arima J, Imazono Y, Takebayashi Y, et al (2000) Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 88:1131-1138
3. Moghaddam A, Zhang HT, Fan TP, et al (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 92:998-1002
4. Imazano Y, Takebayashi Y, Nishiyama K, et al (1997) Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 15:2570-2578
5. Takebyashi Y, Yamada K, Miyadera K, et al (1996) The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 32A:1227-1232
6. Schuller J, Cassidy J, Dumont E, et al (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297
7. Wagstaff AJ, Ibbotson T, Goa KL (2003) Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 63:217-236
8. Fujimoto-Ouchi K, Tanaka Y, Tominaga T (2001) Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5- fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7:1079-1086
9. Sawada N, Ishikawa T, Fukase Y, et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019
10. Takeda Y, Yoshizaki I, Nonaka Y, et al (2001) Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. Anticancer Drugs 12:691-698
11. Kurosumi M, Tabei T, Suemasu K, et al (2000) Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7:945-948
12. Pronk LC, Vasey P, Sparreboom A, et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors. Br J Cancer 83:22-29
13. O'Shaughnessy J, Miles D, Vukeja S, et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
14. Park YH, Ryoo BY, Choi SJ (2004) A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90:1329-1333
15. Ramalingam S, Belani CP (2002) Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother 3:1693-1709
16. 2 weekly in patients with pretreated non-small cell lung cancer. Proc Am Soc Clin Oncol 21:310a
17. Schutte W, Nagel S, Lautenschlager B, et al (2002) Randomised phase III study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 21:308a
18. Theresse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Parise RA, Ramanathan RK, Zamboni WC, et al (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 783:231-236
20. Nadella P, Shapiro C, Otterson GA, et al (2002) Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20:2616-2623
21. Toi M, Bando H, Horiguchi S, Takada M, et al (2004) Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 90:2338-2343
22. Han JY, Lee DH, Kim H, et al (2003) A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer 98:1918-1924
23. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114